North America’s medical devices industry saw a rise of 14.7% in deal activity during May 2019, when compared with the last 12-month average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 86 medical devices industry deals worth $8.23bn were announced for the region in May 2019, against the 12-month average of 75 deals.

Of all the deal types, venture financing saw most activity in May 2019 with 64 transactions, representing a 74.4% share for the region.

In second place was M&A with 19 deals, followed by private equity deals with three transactions, respectively capturing a 22.1% and 3.5% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $7.29bn, while venture financing and private equity deals totalled $876.56m and $55m, respectively.

North America medical devices industry deals in May 2019: Top deals

The top five medical devices deals accounted for 90.7% of the overall value during May 2019.

The combined value of the top five medical devices deals stood at $7.46bn, against the overall value of $8.23bn recorded for the month. The top announced medical devices deal tracked by GlobalData in May 2019 was 3M ‘s $6.73bn acquisition of Acelity .

In second place was the $465m acquisition of VertiFlex by Boston Scientific and in third place was Biomatics Capital Partners , BlueCross BlueShield Venture Partners , Camden Partners Holdings, Casdin Capital , Cowin Venture Capital , Exact Sciences , Gamma3, Section 32 , Invus Group and Third Rock Ventures ‘ $110m venture financing of Thrive Earlier Detection .

The $97m acquisition of Soluble Systems by Misonix and Boulder Ventures, Longwood Fund Management , PBM Capital Group, Peierls Foundation and Perceptive Advisors ‘ venture financing of ArcherDx for $60m held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.